Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPOTLIGHT 204 in resectable basal cell carcinoma
2024-511801-51-00Phase 2Authorised
- Sponsor
- Highlight Therapeutics
- Start
- Oct 2024
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of nanoplexed poly I:C in basal cell carcinoma (BCC) (2 cohorts), sponsored by Highlight Therapeutics. Primary endpoint: Composite visual and pathological response. Planned start Oct 2024; status: authorised.
02
Drugs
nanoplexed poly I:C
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2024-511801-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511801-51-00.